Video

Dr. Eng on Contraindications for Oxaliplatin-Based Therapy in CRC

Author(s):

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

Cathy Eng, MD, FACP, FASCO, David H. Johnson Chair in Surgical and Medical Oncology, co-leader, Gastrointestinal (GI) Cancer Research Program, professor of medicine (hematology and oncology), co-director, GI Oncology, vice chair, SWOG GI Committee, and director, VICC Young Adult Cancers Initiative, Vanderbilt-Ingram Cancer Center, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer (CRC). 

​Patients ​with CRC who are receiving oxaliplatin can develop ​allergic hypersensitivity reactions, says Eng. Moreover, these reactions tend to be delayed and can occur during subsequent cycles of therapy. Oxaliplatin should be stopped in any patients who develop an allergic hypersensitivity reaction.

Additionally, oxaliplatin can cause acute or chronic neuropathy​, Eng says. Acute neuropathy causes cold hypersensitivity and lasts about 5 to 7 days after therapy.​ Chronic neuropathy arises after receiving therapy ​and can be cumulative and prolonged, Eng explains.

Notably, patients with brittle diabetes may have underlying neuropathy. As such, ​diabetic patients with CRC should not receive oxaliplatin-based therapy, Eng concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity